IFRX Latest Press Releases

-- December 30, 2025 --

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum Globe Newswire 7:30 AM

-- December 11, 2025 --

InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 Globe Newswire 7:30 AM

-- November 10, 2025 --

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) Globe Newswire 7:30 AM

-- November 7, 2025 --

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria Globe Newswire 4:05 PM

-- October 21, 2025 --

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference Globe Newswire 7:20 AM

-- September 12, 2025 --

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement Globe Newswire 8:30 AM

-- August 21, 2025 --

InflaRx Announces Participation in September Investor Conferences Globe Newswire 7:30 AM

-- August 7, 2025 --

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software